Horizon Pharma Plc Stock Current Valuation
| HZNPDelisted Stock | USD 100.40 0.13 0.13% |
Valuation analysis of Horizon Pharma PLC helps investors to measure Horizon Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Horizon Pharma's price fluctuation is very steady at this time. Calculation of the real value of Horizon Pharma PLC is based on 3 months time horizon. Increasing Horizon Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Horizon Pharma's intrinsic value may or may not be the same as its current market price of 100.40, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 100.4 | Real 87.02 | Hype 100.4 | Naive 101.54 |
The intrinsic value of Horizon Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Horizon Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Horizon Pharma PLC helps investors to forecast how Horizon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Horizon Pharma more accurately as focusing exclusively on Horizon Pharma's fundamentals will not take into account other important factors: Horizon Pharma PLC Company Current Valuation Analysis
Horizon Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Horizon Pharma Current Valuation | 26.87 B |
Most of Horizon Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Horizon Pharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Horizon Pharma PLC has a Current Valuation of 26.87 B. This is 87.1% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 61.65% lower than that of the firm.
Horizon Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Horizon Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Horizon Pharma could also be used in its relative valuation, which is a method of valuing Horizon Pharma by comparing valuation metrics of similar companies.Horizon Pharma is currently under evaluation in current valuation category among its peers.
Horizon Fundamentals
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 98.82 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | 32.55 X | |||
| Price To Book | 5.10 X | |||
| Price To Sales | 6.93 X | |||
| Revenue | 3.63 B | |||
| Gross Profit | 2.8 B | |||
| EBITDA | 1.11 B | |||
| Net Income | 521.48 M | |||
| Cash And Equivalents | 2.13 B | |||
| Cash Per Share | 9.40 X | |||
| Total Debt | 2.56 B | |||
| Debt To Equity | 0.53 % | |||
| Current Ratio | 3.96 X | |||
| Book Value Per Share | 23.20 X | |||
| Cash Flow From Operations | 1.26 B | |||
| Short Ratio | 2.04 X | |||
| Earnings Per Share | 1.88 X | |||
| Price To Earnings To Growth | 1.00 X | |||
| Target Price | 116.5 | |||
| Number Of Employees | 2.19 K | |||
| Beta | 1.01 | |||
| Market Capitalization | 26.63 B | |||
| Total Asset | 9.11 B | |||
| Retained Earnings | 590.01 M | |||
| Working Capital | 2.7 B | |||
| Current Asset | 1.11 B | |||
| Current Liabilities | 357.55 M | |||
| Z Score | 7.48 | |||
| Net Asset | 9.11 B |
About Horizon Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Horizon Pharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Horizon Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Horizon Pharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Horizon Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Horizon Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Horizon Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Horizon Stock
| 0.84 | SSNLF | Samsung Electronics | PairCorr |
| 0.79 | PTAIF | PT Astra International | PairCorr |
| 0.77 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.76 | XOM | Exxon Mobil Corp Sell-off Trend | PairCorr |
| 0.72 | HD | Home Depot | PairCorr |
The ability to find closely correlated positions to Horizon Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Horizon Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Horizon Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Horizon Pharma PLC to buy it.
The correlation of Horizon Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Horizon Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Horizon Pharma PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Horizon Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |